Literature DB >> 18410781

Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families.

David J Coman1, Ian M Hayes, Veronica Collins, Margaret Sahhar, J Ed Wraith, Martin B Delatycki.   

Abstract

OBJECTIVES: To assess the opinions of individuals with mucopolysaccharidoses (MPS) and their parents regarding the use of enzyme replacement therapy (ERT). STUDY
DESIGN: A validated questionnaire, including hypothetical clinical scenarios about ERT for MPS, was distributed to members of MPS support groups in the United States and Australia.
RESULTS: The questionnaire was completed by 249 MPS support group members. Overall, 92% were in favor of ERT where MPS causes severe physical problems but does not affect intellect, and 69% were in favor of ERT where the physical limitations are mild and intellect is spared. Only 47% were in favor of ERT where severe physical and intellectual problems are well established; however, 77% were in favor of ERT in this situation if treatment begun early prolongs life and improves quality of life.
CONCLUSION: Most respondents were in favor of ERT for MPS, even where it would not alter the intellectual deterioration. The medical community has a responsibility to advocate for their patients in situations where ERT is appropriate and recognize the economic burden and "family function burden" ERT can incur.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410781     DOI: 10.1016/j.jpeds.2007.10.015

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians.

Authors:  David J Coman; Ian M Hayes; Veronica Collins; Margaret Sahhar; J Ed Wraith; Martin B Delatycki
Journal:  JIMD Rep       Date:  2011-06-22

2.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

3.  Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families.

Authors:  R Freedman; M Sahhar; L Curnow; J Lee; H Peters
Journal:  J Genet Couns       Date:  2013-03-28       Impact factor: 2.537

4.  The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus.

Authors:  Joseph Muenzer; Olaf Bodamer; Barbara Burton; Lorne Clarke; Gudrun Schulze Frenking; Roberto Giugliani; Simon Jones; Maria Verónica Muñoz Rojas; Maurizio Scarpa; Michael Beck; Paul Harmatz
Journal:  Eur J Pediatr       Date:  2011-10-29       Impact factor: 3.183

Review 5.  Enzyme replacement therapy: efficacy and limitations.

Authors:  Daniela Concolino; Federica Deodato; Rossella Parini
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

6.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12

7.  Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.

Authors:  Christina Lampe; Ann-Kathrin Bosserhoff; Barbara K Burton; Roberto Giugliani; Carolina F de Souza; Camila Bittar; Nicole Muschol; Rebecca Olson; Nancy J Mendelsohn
Journal:  J Inherit Metab Dis       Date:  2014-03-05       Impact factor: 4.982

8.  Bioinformatic Analysis of the Human Recombinant Iduronate 2-Sulfate Sulfatase.

Authors:  Edwin D Morales-Álvarez; Claudia M Rivera-Hoyos; Patricia Landázuri; Raúl A Poutou-Piñales; Aura M Pedroza-Rodríguez
Journal:  Open Microbiol J       Date:  2016-05-31

9.  Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique.

Authors:  M R Oliveira; I Schwartz; L S Costa; H Maia; M Ribeiro; L B Guerreiro; A Acosta; N S Rocha
Journal:  BMC Res Notes       Date:  2018-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.